Autozygosity, meaning inheritance of an ancestral allele in the homozygous state is known to lead bi-allelic mutations that manifest their effects through the autosomal recessive inheritance pattern. Autosomal recessive mutations are known to be the underlying cause of several Mendelian metabolic diseases, especially among the offspring of related individuals. In line with this, inbreeding coefficient of an individual as a measure of cryptic autozygosity among the general population is known to lead adverse metabolic outcomes including Type 2 diabetes (T2DM); a multifactorial metabolic disease for which the recessive genetic causes remain unknown. In order to unravel such effects for multiple metabolic facades of the disease, we investigated the relationship between the excess of homozygosity and the metabolic signature of T2DM. We included a set of 53 metabolic phenotypes, including 47 metabolites, T2DM and five T2DM risk factors, measured in a Dutch genetic isolate of 2,580 people. For 20 of these markers, we identified 29 regions of homozygous (ROHs) associated with the nominal significance of P-value < 1.0 × 10 -3 . By performing association according to the recessive genetic model within these selected regions, we identified and replicated two intronic variants: rs6759814 located in KCNH7 associated with valine and rs1573707 located in PTPRT associated with IDL-free cholesterol and IDL-phospholipids. Additionally, we identified a rare intronic SNV in TBR1 for which the homozygous individuals were enriched for obesity.
Introduction

1
Consanguineous marriages between close relatives as a result of assertive mating is known to cause 2 severe metabolic diseases in the off-spring (VERNON 2015) . In addition to that, moderate inbreeding due to isolation 3 in populations has been shown to cause unfavorable outcomes among with cardio-metabolic and neuropsychiatric 4 parameters (VERWEIJ et al. 2014; HOWRIGAN et al. 2016 ). The previous report shows evidence that inbreeding 5 associates with an increase in blood pressure, glucose and decrease in high-density lipoprotein cholesterol (HDL-6 C), intelligence quotient (IQ) and height (MCQUILLAN et al. 2012 ). In the decade, technological advances in 7 metabolomics allow researchers to capture the biochemical status in an organism. As one of the most common 8 metabolic disorders, studying the metabolomics of type 2 diabetes (T2DM) is particularly promising as the 9 deregulation of biochemical processes is involved in the pathophysiology of T2DM. In line with this, many 10 circulating metabolites have been found associated with T2DM: including phospholipids, branch-chain amino-acids 
12
In our previous report, we tested the evidence of recessive SNP effects. We revealed that six out of the 13 eight quantitative metabolite genetic loci showed a recessive rather than an additive effect on the metabolite 14 (DEMIRKAN et al. 2015) . This raises an important question of whether such recessive variants are relevant for 15 metabolic diseases such as T2DM and its markers. In order to answer this question and find genetic loci that act 16 under recessive inheritance, we first defined runs of homozygosity (ROHs) that relate to T2DM and its circulating 17 profile in blood in the genetically isolated ERF population and then looked for the causal recessive variants within 18 the loci using coding variants. We focused on a set of 47 metabolites which we selected based on their correlation 
24
Methods
25
Study population
26
The Erasmus Rucphen Family genetic isolate study (ERF) is a prospective family-based study located in
27
Southwest of the Netherlands. This young genetic isolate was founded in the mid-eighteenth century and minimal 
34
and were invited to the research center for an interview and blood collection for biochemistry and physical
35
examinations including blood pressure and anthropometric measurements have been performed. The participants
36
were asked to bring all their current medications for registration during the interview. Venous blood samples were 37 collected after at least eight hours of fasting. Baseline type 2 diabetes was defined according to the fasting plasma 38 glucose ≥ 7.0mmol/L and/or anti-diabetic treatment, yielding 212 cases and 2,564 controls, totaling up to 2,776.
39
The follow-up data collection of the ERF study took place in May 2016 (9 to 14 years after baseline visit 
123
Imputation-based genetic variants
124
The SNPs with less than five minor allele counts were excluded. The exclusion criteria for SNPs were HWE
125
with P-value < 1.0 × 10 -6 or SNP call rate < 98%. The associations of the significant metabolites within the genotype 
132
Candidate genes within the ROH were selected by in-house developed automated pathway search 
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Results
139
ROH regression analysis
163
For each locus, the association for the minor allele under the recessive models has been tested, results
164
are shown in Table 2a and Table 2b with sequence and chip-based genotyping sets respectively. We used three 
192
In order to investigate the effect of these variants in the outbred population, Rotterdam Study we set out 193 a replication. Out of the 18 genetic associations coming either from exome sequencing, exome chip or imputation 194 sets, we were able to test 12 in the Rotterdam study as 6 of the phenotypes were not available for replication.
( 
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whereas the other homozygous individual is overweight (Table 6 ).
210
Discussion
211
We report an in-depth association mapping effort for a total of 53 selected metabolic phenotypes by using 212 three sets of independently generated genotype data. 
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are marked in italic/bold; Chip/Seq/1000G: indicating the genotyping platform of the variant in discovery and replication phase. 
